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PDN-21 (Katacalcin) and Chromogranin A: Tumor Markers for
Medullary Thyroid Carcinoma

Friedhelm Raue,* Eberhard Blind,* and Andreas Grauer*

The malignant C-cell releases several markets of potential clinical .significance into the circulation.
To determine the usefulness of these markersfor management of medullary thyroid carcinoma (MTC),
it is necessary to compare the usefulness ofthese markers with calcitonin (CT), the classical tumor
marker for MTC. Measurement of serum concentrations of the peptide PDN-21 (katacalcin), a
carboxyterminal cleavage product of procalcitonin. showed a high correlation with serum CT levels
(r = 0.99, P < O.OI, n = 65 patients with MTC). The presence of equimolar concentrations of CTand
PDN-21 (CT/PDN-21 molar ratio = 0.95 ± 0.33) indicates the peptide is cosecreted with CT.
Stimulation of CT release by intravenous pentagastrin was associated with a parallel increase of
PDN-21, providing further evidence of cosecretion of these two peptides. Finally, measurement of
either PDN-21 or CT in selective venous catheterization specimens was useful for localization of
MTC. Chromogranin A (CgA) levels were also measured in patients with MTC. Circulating levels
were elevated in most patients with advanced disease. There was a moderate correlation berween
CgA and CT serum levels (r = 0.87, P < 0.01. n = 61 patients with MTC). Pentagastrin did not
stimulate CgA, and the long half-life of CgA in the circulation did not make it possible to use this
peptide for tumor localization by selective venous catheterization. We conclude that measurement of
PDN-21 provides an independent assay system for diagnosis, localization, and postoperative
management of MTC. whereas CgA measurement is not useful in early diagnosis of MTC and is of
limited value for localization or management of progressive disease. (Henry Ford Ho.sp Med J
1992;40:296-8)

M

alignant C-cells are able to release several biologically
active substances into the circulation (Table 1). During
the last 20 years, several of these secretory products have been
tested as markers for medullary thyroid carcinoma (MTC), but
only a few have achieved clinical importance. Calcitonin (CT),
the main peptide derived from the CT gene, is released from normal and malignant C-cells and its usefulness as a serum marker
of MTC is well established. Another peptide derived from the
CT precursor peptide is a 21-amino acid C-terminal flanking
peptide, PDN-21 or katacalcin (1). It has already been tested as
a marker for MTC, but it is less often used for the diagnosis of
MTC than CT (2-6).
Chromogranin A (CgA), a 431-amino acid protein involved
in intracellular packaging and processing of peptide hormones
and neuropeptides, is a prototype of the "neuroendocrine"
marker family (7). It is found in many neuroendocrine tissues,
and circulating levels can be elevated in patients with tumors of
these tissues such as pheochromocytoma, parathyroid adenoma,
insulinoma, and carcinoid (8). As the deterniination of CT is still
the "gold standard" for investigation of MTC patients, it is important to compare new markers to measurement of serum CT in
a variety of ctinical situations to determine the usefulness of the
marker. In this study we evaluated the usefulness of plasma CgA
and seram PDN-21 with seram CT in patients with MTC to determine the relative usefulness of these markers.
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Patients and Methods
Plasma from 61 patients (29 women and 32 men) with histologically proven MTC at different stages of the disease with either the sporadic (n = 46) or the familial (n = 15) variety of the
disease was measured in a radioimmunoassay (RIA) for CgA or
CT. PDN-21 and CT were compared in 65 patients with proven
MTC. The response to pentagastrin (0.5 |r.g/kg body weight, intravenously) was tested in nine patients with MTC. In one patient with MTC who had a postoperative elevation of CT levels,
selective venous catheterization with blood sampling for determination of CT, PDN-21, and CgA was done. Plasma CT levels
were determined by an in-house RIA (9). The normal range for
this assay is < 0.05 to 0.2 ng/mL. PDN-21 plasma levels were
determined by RIA using a goat antiseram (G 47-8/89), '--^I
TyrO-PDN-21 as a tracer, and synthetic PDN-21 as standard (6).
The reference range for this assay is < 10 to 40 pg/mL. CgA in
plasma was measured by RIA (10) with slight modification
( I I ) ; this assay has a detection limit of 7 ng/mL and an upper
limit of the reference range of 50 ng/mL.
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Table 1
Substances Produced or Released by
Medullary Thyroid Carcinoma
Peptides derived from the calcitonin gene:
Calcitonin (CT)
PDN-21 (katacalcin)
PAS-57
Calcitonin gene-related peptide (CGRP)
Neuroendocrine markers:
Chromogranin A (CgA)
Neuron-.specific enolase (NSE)
Synaptophysin
7B2
HISL-I9
Peptide hormones and releasing factors:
Somatostatin (SRIF)
Gastrin-releasing peptide (GRP)
Adrenocorticotropic hormone (ACTH)
Parathyroid hormone-related protein (PTHrP)
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Fig J—Plasma levels of calcitonin (lefr panel, n = 9), PDN-21
(middle panel, n = 9), and CgA (right panel, n = 7) before and
after stimulation with pentagastrin (0.5 ytg/kg body weight intravenously) in patients with MTC. (CT values helow 0.04 ngl
mL were considered to be below the limit of detection of the assay.)

Others:
Carcinoembryonic antigen (CEA)
Histaminase
L-Dopadecarboxylase
Helodermin
Prostaglandin
Tissue polypeptide antigen (TPA)

Results
Linear regression analysis of the basal levels of PDN-21 and
CT in 65 patients with MTC gave a slope of r = 0.99 (P < 0.01);
the average ratio of CT/PDN-21 was 0.96 ± 0.33 (mean ± SD).
The average molar ratio of CT/PDN-21 for pentagastrin tests
was 1.45 for basal values and became nearly equimolar during
pentagastrin stimulation (Fig 1). In serum samples collected
during selective venous catheterizations, the concentrations of
PDN-21 as well as CT were highest at the site of the suspected
MTC tissue (Fig 2). The exact localization was subsequently
confirmed by operation. Basal levels of CgA and CT in 61 patients with MTC correlated significantly (r = 0.87, P < 0.01), but
CgA was elevated into the abnormal range in only 23% of cases,
mainly in progressive disease (CT > 10 ng/mL, CgA elevated in
83.3%) (Table 2). In response to pentagastrin, no change in CgA
levels was observed (Fig 1). In selective venous catheterization
blood sampling studies, no gradient was observed for CgA (Fig
2).

Discussion
These studies demonstrate clearly that PDN-21 and CT are
comparable for diagnosis of MTC. This is true for basal measurements and pentagastrin-stimulated values, a point which
has been demonstrated previously for only small numbers of patients (2,4,5). These results also indicate that PDN-21 and CT
are secreted in equimolar amounts in patients with MTC. This
was confirmed by measurement in both peripheral venous samples and in samples obtained during selective venous catheterization, the latter a more direct indication of secretion by the tumor. It is our belief that PDN-21 is as good a tumor marker for
MTC as CT, although for historical reasons CT is most commonly used for diagnostic purposes. However, PDN-21 may be
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Fig 2—Concentrations of CT (left), PDN-21 (middle), and CgA
(right) (in ng/mL) in serum samples obtained hy selective venous catheterization from a patient with MTC (the values shown
are in ng/mL of serum). MTC tissue at the right side ofthe neck
was confirmed by operation.

helpful for clarification of the diagnosis of MTC in patients with
borderline pentagastrin test results.
The usefulness of CgA determination in the plasma of MTC
patients is limited as only patients with advanced disease have
elevated CgA levels. Measurement of CgA was not useful for
detection of early cases of MTC because basal levels are in the
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Table 2
Elevated Chromogranin A Levels in 61 Patients
with Medullary Thyroid Carcinoma

CT
(ng/mL)
<0.2
0.2-10
> 10

Chromogranin A
Mean
Percent
(ng/mL)
Elevated
16,0
12.0
806

7.1%
15.4%
83.3%

n
14
41
6

normal range and do not increase after pentagastrin stimulation.
In addition, several sources of CgA may exist in MEN 2 including the adrenal, parathyroid, or the CT-producing cells. We conclude that measurement of CT remains the "gold standard" as a
tumor marker for diagnosis of MTC. PDN-21 is cosecreted with
CT and may be used as a second independent marker to clarify
the diagnosis in borderline cases. CgA is useful as a marker only
in patients with progressive sporadic MTC.
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